Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the ...

Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration said on Friday.

The Food and Drug Administration said on Friday that the shortage of semaglutide injection products, such as Novo Nordisk's Wegovy, has been resolved. FDA's update led to renewed uncertainty for a ...

The semaglutide shortage has officially ended in the US—which means the GLP-1 drug industry is about to undergo massive ...

The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

The FDA has declared an end to the shortage of Novo Nordisk’s blockbuster drug semaglutide, threatening the ability for ...

A randomized, placebo-controlled trial validates a side effect frequently observed by doctors and patients. A new study from ...

Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...

Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...